Page **1** of **27**



Page **2** of **27**

36

#### <sup>37</sup>Abstract



55

#### 56 Introduction

57 Type 2 diabetes is global problem of increasing proportions and a substantial threat to<br>human health (1). Recently, Ahlqvist et al. (2) proposed an approach to sub-classifying 58 patients with type 2 diabetes into four different subgroups by K-means clustering using 59 six clinical measurements: age at diagnosis, Body Mass Index (BMI), Glutamic acid 60 six clinical measurements: age at diagnosis, Body Mass Index (BMI), Glutamic acid

#### Page **3** of **27**



In the present study, we performed distributed analysis of two independent patient cohorts to explore the stratification of type 2 diabetes based on combined plasma 85 cohorts to explore the stratification of type 2 diabetes based on combined plasma  $\mathbf{r}$ 

Page **4** of **27**

- 86 lipidomics and peptidomics using a federated database system. In addition, we explore<br>the genetic factors predisposing to membership in these groups and the potential
- 87
- the genetic factors with patient molecular profiles and the potential series and the potential the po 88 correlations with patient models with patient models.<br>Mothods
- 89
- 90 Methods
- 91 Study populations
- 92 We used data from two type 2 diabetes cohorts: Hoorn Diabetes Care System (DCS) and<br>Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) .
- 93
- The DCS cohort recruits almost all type 2 diabetes patients from 103 GPs in the West-<br>Friesland region of the Netherlands. This prospective, regional cohort study started in 94
- 95
- $1009$  and by the time of  $2017$  it holds  $12.672$  type 2 dispetes patients with a median Friesdale region of the Netherlands. This prospective, regional cohors reduly started in the Netherlands. This provision of  $2017$ , it holds  $12,673$  type 2 diabetes patients with a median of  $7$  vears (IQD 0.2.2.7) often 96
- $0.7$  years (IQR  $0.2-3.7$ ) after diagnosis  $(10)$ . 97
- 98
- Between 1996 and 2015, GoDARTS recruited 10149 type 2 diabtes patients from the 99
- Tayside region of Scotland. Patients in the GoDARTS cohort were not necessarily<br>recruited at the time of diagnosis (11). 100
- Tayside recruited at the time of diagnosis (11).<br>The Scotlanders in the Godards control were not necessarily were not necessarily were not necessarily were not 101
- 102
- Lipidomics and peptidomics are available for a subset of type 2 diabetes patients in 103
- both DCS and GoDARTS cohorts. These data were generated as part of the IMI2 104
- RHAPSODY project (3). The sample availability for omics was within 2 years of 105
- diagnosis. Of note, individuals were selected without taking into consideration pre-<br>cluster assignments. 106
- 107 cluster assignments.
- 108
- 109
- 110

Page **5** of **27**

#### 111 Measurements



123

### 124 Cluster analysis

125 A federated database of type 2 diabetes cohorts including DCS and GoDARTS has<br>previously been set up as part of the RHAPSODY project. This system enables statistical 126 and machine learning analysis to be performed on cohort data at a distance without any 127 disclosure of sensitive data. The federated database system was interrogated using the 128 R statistical programming language (version  $4.0.4$ ). In both DCS and GoDARTS cohorts, 129 patients with complete lipidomics and peptidomics (589 and 545 patients, DCS and 130 GoDARTS, respectively) were used for clustering and subsequent statistical analysis. 131 Lipidomics and peptidomics values were centered to a mean value of  $0$  and an SD of 1 in 132 each cohort using the *scale* function in R. Euclidean distances between each pair of 133 patients were then calculated based on the normalized lipidomics or peptidomics data 134 patients were then calculated based on the normalized lipidomics or peptidomics data<br>by using *dist2* function from *dssSNF* (*dsSwissKnifeClient* package) (12). Patient similarit 135 by using *dist2* function from *dssSNF (dsSwissKnifeClient* package) (12). Patient similarity<br>distribution of the Swiss Andre Statent similarity

#### Page **6** of **27**



The possibility of using clinical measurements to replicate our multi-omics clustering 159 results was assessed in a logistic regression model with pseudo R square as the 160 results was assessed in a logistic regression model with pseudo R square as the sq

Page **7** of **27**



168 **Statistical analysis**<br>169 Logistic regression modelling was performed by using the *ds.glm* function within the<br>170 *dsBaseClient* package to assess the association level of each molecule (lipidomics and 169 dsBaseClient package to assess the association level of each molecule (lipidomics and peptidomics), clinical measurements and type 2 diabetes SNPs (17) with the multi-<br>omics clusters. The cluster classification was treated as a dependent categorical variable 171 perith age, gender and DMI esting as severistes Subsequently, for limids, neutides an 172 omics clusters. The cluster clusters was treated as a dependent categorical variable<br>with age, gender and BMI acting as covariates. Subsequently, for lipids, peptides and<br>slinical measurements, aseb slugter was subset for 173 clinical measurements, each cluster was subset for the strongly associated (P-value 174  $\leq$ =0.05) features and the mean values of each group of features in each cluster were 175 calculated. Mean values were used since, to protect the patient's identity, individual-176 level data cannot be downloaded from the federated database system. However, it is 177 possible to display a mean value if it is derived from 5 or more patients. Several mean 178 values for each feature from 5 or more patients were calculated based on the default 179 patients' order in the remote server for each cluster. The feature values were 180 normalized. Hierarchical clustering was then performed, and the results were visualized 181 as heatmaps using the R package *gplots*  $(18)$ . 182 as heatmaps using the R package *gplots* (10).<br>For each notient in the detehoos, the clinical

183

184 For each patient in the database, the clinical cluster assignments were defined<br>previously, similar to (2), but with five clinical variables: age, BMI, HbA1c, high-density 185 previously, since clinical variables: and but with five clinical variables: and age, BMI, HbA1c, high-density,<br>In the case of the contract of

# Page **8** of **27**



Page **9** of **27**



assessment (HOMA) 2, HOMA2-B and HOMA2-IR, which were calculated based on  $\mathcal{A}$ 

#### Page **10** of **27**



In summary, by 259 unsupervised analysis, we were able to separate type 2 diabetes patients from two 260 unsupervised analysis, we were able to separate type 2 diabetes patients from two

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.03.22279563;](https://doi.org/10.1101/2022.09.03.22279563) this version posted September 4, 2022. The copyright holder for this preprint

Page **11** of **27**

- 261
- $\begin{array}{ccc}\n\bullet & \bullet & \bullet \\
\bullet & \bullet & \bullet\n\end{array}$ <br>clinical characteristics. 262
- 263

# clinical characteristics.<br>Similar molocular cice 264 Similar molecular signatures separate subgroups in both cohorts

- 265 We investigated the correlation of each plasma lipidomics or peptidomics feature with<br>the clustering results using logistic regression models adjusting for gender, BMI and
- 266
- age. In DCS, out of a total of 1195 different peptides and 180 different lipids that were 267
- used for clustering, 123 proteins and 137 lipids showed significant differences between 268
- clusters. In GoDARTS, out of a total of 1195 different peptides and 199 different lipids 269
- that were used for clustering, 130 proteins and 149 lipids showed significant 270
- differences between clusters. 50 significant common peptides and 109 significant 271
- common lipids are shared between the DCS and GoDARTS cohorts (Figure 2b). 272
- 273
- A hierarchical clustering of the relative concentration patterns of the cluster-274
- 275
- a hierarchical clustering of the relative concentrative concentrative concentrative concentration patterns of t componental Figure 5). In DCS, a number of discriminative omics features v<br>absorved when someoring slusters. Phosphatidylabeline. Triacylalyserel. Di 276
- observed when comparing clusters. Phosphatidylcholine, Triacylglycerol, Diacylglycerol 277
- and Ceramide were relatively higher in cluster 1; Phosphatidylcholine O and 278
- Sphingomyelin were relatively higher in cluster 2. These pronounced expression 279
- patterns were also apparent in GoDARTS. For proteins, the difference in the molecular 280
- profiles between cluster 1 and 2 can be observed in both cohorts, but the differences<br>were more modest compared to lipids. 281
- profiles between cluster 1 and 2 can be observed in both cohors, but the differences<br>were more modest compared to lipids. 282 were modest compared to  $\frac{1}{\sqrt{2}}$
- 283
- 284

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.03.22279563;](https://doi.org/10.1101/2022.09.03.22279563) this version posted September 4, 2022. The copyright holder for this preprint

Page **12** of **27**

#### <sup>285</sup>GWAS analysis reveals putative associations between type 2 diabetes molecular

#### 286 profiles and genetic factors

- 287 Finally, in order to investigate possible genetic differences between molecular clusters,<br>we analysed genetic loci previously associated with type 2 diabetes (17). Multi-omics
- 288
- clusters in each cohort were compared with type 2 diabetes SNPs using logistic 289
- regression correcting for age, BMI and gender. We did not detect any significant 290
- associations of the type 2 diabetes variants with our clusters in either cohort. 291
- Since we had identified around 110 proteins and 130 lipids that showed altered levels 292
- between clusters, we then tested the association between the altered molecular profiles 293
- and type 2 diabetes variants. The SNP and molecular profile association was assessed in 294
- a linear regression model with SNP dosages, age, BMI and gender as independent 295
- variables. In DCS, a novel protective type 2 diabetes variant  $(17)$ , rs146886108, showed 296
- putative association with several molecules such as heat shock protein 90 beta ( $p$ ) 297
- =1.08e-13) and glucose 6 phosphate isomerase ( $p = 2.04e$ -15). A consistent association 298
- result between rs505922 and E-selection can also be observed in both DCS ( $p = 1.23e-15$ ) and GoDARTS ( $p = 1.40e-16$ ) cohorts. 299

result between rs505922 and E-selection can also be observed in both DCS  $(p - 1.23e$ -<br>15) and GoDARTS ( $p = 1.40e-16$ ) cohorts. 300

301

# 15) and GoDARTS  $(p - 1.40e^{-1}$ OJ cohorts.<br>Multi-Amics clusters show similarity to <sup>302</sup>Multi-Omics clusters show similarity to known clinical subgroups

303

We next compared the multi-omics clusters with clusters based on clinical<br>measurements (3). Similar to a previous study (2), these clusters can be classified as 304

severe insulin-deficient diabetes (SIDD); severe insulin-resistant diabetes (SIRD); mild 305

- obesity-related diabetes (MOD); mild diabetes (MD) and mild diabetes with high HDL 306
- (MDH). The overlap of clinical clusters with molecular clusters is shown in figure 3a. In 307
- DCS, multi-omics cluster 1 showed a significant overlap with clinical cluster SIRD and 308
- MOD. On the other hand, multi-omics cluster 2 showed a significant overlap with clinical 309  $M_{\odot}$  and  $M_{\odot}$  multi-omic cluster 2 showed a significant overlap with clinical overlap with clinical overlap with clinical order  $\alpha$

#### Page **13** of **27**



In both the DCS and GoDARTS cohorts, patients<br>are complementary to choose are completed differences in discass sever 332 2 showed conserved differences in disease severity markers as measured by HOMA2-B, 333

-IR, C-peptide and triglyceride levels, which is known to be associated with insulin 334  $I = \frac{1}{2}$ ,  $\frac{1}{2}$ ,

# Page **14** of **27**



# Page **15** of **27**



It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.03.22279563;](https://doi.org/10.1101/2022.09.03.22279563) this version posted September 4, 2022. The copyright holder for this preprint

#### Page **16** of **27**



387

#### <sup>388</sup>Limitations of study

- 389 From the patient network (Figure 1) it is clear that the multi-omics clusters are not<br>completely distinct. The two clusters therefore represent different molecular
- 390
- signatures, where a patient shows more similarity to one cluster compared to the other 391

on a continuous scale. Nevertheless, we do not recommend using such clusters to assign 392

- patients, but rather the use of the clustering results to explore the underlying molecular 393
- pathology and as an alternative route to identifying novel biomarkers for risk of type 2<br>diabetes and its complications. 394
- 395

pathology and as and its complications.<br>The bath DCS and CoDAPTS, notiontalizers for reasonability required after diagnosis, and In both DCS and GoDARTS, pat<br>this hatare consity in the disease 396

this heterogeneity in the disease duration could potentially have an effect on the blood 397

measurements obtained. Moreover, as we mentioned above, in DCS, blood samples are 398

taken in a fasted state, in contrast to GoDARTS, where blood measurements are done in 399

a non-fasted state. However, it has been demonstrated that a normal food intake only 400

has slight effects on cholesterol levels, and lipid profiles at most change minimally in 401

response to normal food intake in general populations (23, 24). 402

One of the common questions regarding patients' clustering results is whether patients 403 move between clusters over time. In a recent 5-year follow-up study (25), 367 diabetes 404 patients were assigned based on the nearest centroid approaches at both baseline and 405 5-year follow-up. 23% of patients switched their cluster allocations after 5 years. This 406 can be expected as the variables that were used for clustering such as age, BMI and 407 HOMA2 can change over time, following the time increase, lifestyle choice changes and 408

disease progress. For our study, roughly 1375 plasma molecules were used for 409 disease progress. For our study, roughly 1375 plasma molecules were used for

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.03.22279563;](https://doi.org/10.1101/2022.09.03.22279563) this version posted September 4, 2022. The copyright holder for this preprint

#### Page **17** of **27**

- 410 clustering. Some molecule concentrations such as triacylglycerol and diacylglycerol can<br>change following lifestyle changes or medical treatment. Other "housekeeping"
- 411
- molecules are more likely to remain constant over time. The stability of molecular 412
- clustering results needs to be assessed in further prospective studies. 413
- We cannot at this stage assert that the different clusters represent different aetiologies. 414
- of type 2 diabetes, nor that the clustering method represents an optimal classification 415
- for type 2 diabetes subgroups. The multi-omics clusters in our study were derived 416
- primarily from patients from Europe. Consequently, the applicability of these results to 417
- other ethnic groups needs to be assessed. 418 other ethnic groups in the assessed.
- 419

#### 420 Acknowledgments

- 421 The authors acknowledge the support of the Health Informatics Centre, University of<br>Dundee, for managing and supplying the anonymized data.
- 422
- **Funding.** G.R. was supported by a Wellcome Trust Investigator Award 423 Funding. G.R. was supported by a Wellcome Trust Investigator Award<br>424 (212625/Z/18/Z), MRC Programme grant (MR/R022259/1) Diabetes UK
- 424
- $(BDA/15/0005275, BDA 16/0005485)$  grants and a start-up grant from the CR-CHUM, 425
- Université de Montréal. This project has received funding from the Innovative 426
- Medicines Initiative 2 Joint Undertaking, under grant agreement no.  $115881$ 427
- (RHAPSODY). This Joint Undertaking receives support from the European Union's 428
- Horizon 2020 research and innovation programme and EFPIA. This work is supported 429
- by the Swiss State Secretariat for Education, Research and Innovation (SERI), under<br>contract no. 16.0097. 430
- 431
- $b$  by the Swiss State Secretariation's Education, problem and innovation (SERI), under<br>contract no. 16.0097. **Duality of Interest.** G.A.R. has received grant funding from, and is a consultant for, Sun **132 Duality of Interest.** G.A.R. has received grant funding from, and is a consultant for, Sun<br>133 Pharmaceuticals Inc. K.S. is CEO of Lipotype. K.S. and C.K. are shareholders of Lipotype.
- 433
- M.JG. is an employee of Lipotype. M.K.H. is an employee of Janssen Research & 434 M.J. is an employee of Lipotype. M.K.H. is an employee of  $\mathbb{R}^n$  is an employee of  $\mathbb{R}^n$

#### Page **18** of **27**

- 435 Development. All other authors declare that there are no relationships or activities that<br>might bias, or be perceived to bias, their work.
- 436
- **Contribution Statement.** S.L., M.I. and G.A.R. designed the research. S.L. wrote the
- **Contribution Statement.** S.L., M.I. and G.A.R. designed the research. S.L. wrote the<br>438 manuscript. S.L. performed all data analysis with technical support from I.D.. I.D., D.K.,<br>439 and M.I. set up a federated node syst 438
- and M.I. set up a federated node system for data analysis. R.C.S., L.A.D., M.K.H., J.W.J.B.,
- L.M't.H., F..M, P.J.M.E. and E.R.P. were involved in generating the peptidomics data, 440
- generating the clinical cluster assignment results, managing and handling the data in 441
- databases. M.JG., C.K. and K.S. generated the Lipotype data. The research was designed 442
- partly based on the pre-work results by C.H.F. All authors read and approved the 443
- manuscript and contributed according to the  $ICMIE$  criteria (www.icmje.org/). G.A.R. 444
- and M.I. co-supervised the work. M.I. is the guarantor of this work and, as such, had full 445
- access to all the data in the study and takes responsibility for the integrity of the data 446
- access to all the data in the study and takes responsibility for the integrity for the integrity<br>and the accuracy of the data analysis. 447 and the accuracy of the data analysis.<br>448<br>.
- 448

Page **19** of **27**

# Table 1. Genetic associations with altered molecular profiles between multi-<br>450 omics clusters reaching significance. The correlations between molecules and SNPs

- 
- were estimated using linear regression models with age, BMI and gender adjustments. 451
- The commonly accepted threshold  $P \le 5 \times 10(-8)$  for genome-wide association studies is applied in this present study. 452
- 453



# Page **20** of **27**



456

Page **21** of **27**

#### 457 References



# Page **22** of **27**



# Page **23** of **27**



Page **24** of **27**



- fasting and non-fasting lipid measurements is not related to statin treatment.<br>Ann Transl Med. 2021 Mar;9(5):386. 528
- fasting and non-fasting lipid measurements is not related to stating a stating.<br>Ann Transl Med. 2021 Mar;9(5):386.<br>Zaharia OB Streesburger K. Strem A. Bärkef GL Kerwebays X. Arteniau S. at al 529
- $\frac{1}{2}$ Zaharia OP, Strassburger K, Strom A,  $\frac{1}{2}$ 530
- Risk of diabetes-associated diseases in subgroups of patients with recent-onset 531
- diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019<br>Sep;7(9):684–94. 532
- $\mathsf{Sep}; 7(9): 684-94.$ 533  $\mathbf{S}$
- 534
- 535
- 536
- 537
- 538

It is made available under a CC-BY-NC 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.03.22279563;](https://doi.org/10.1101/2022.09.03.22279563) this version posted September 4, 2022. The copyright holder for this preprint

Page **25** of **27**

#### 539 Figure legends

# 540 Figure 1. Experiment design and the molecular clusters displayed as both<br>541 Similarity matrices and patient network. (b,c) Molecular clusters were generated by integrated multi-omics (lipidomics and peptidomics) data in both  $DCS$  (b) and  $GoDARTS$ 542 (c), respectively. The similarity matrices were calculated based on Euclidean distances 543 with parameters of K=20 (the number of shared neighbours of datapoint), alpha=0.5 544 (hyperparameter) and  $T=20$  (number of iterations). Each point in the similarity 545 matrices represents patient-to-patient similarity, the higher the colour intensity, the 546 more similar the patients. Boxed regions represent the potential clusters. The patient 547 networks were generated based on unweighted adjacency matrices. The nodes 548 represent the patients, edge thickness reflects the strength of similarity, the size of the 549 node represents the betweenness. Nodes were coloured based on their cluster 550 assignments. DCS= Hoorn Diabetes Care System. GoDARTS=Genetics of Diabetes Audit<br>and Research in Tayside Scotland. 551 assignments. DCS= Hoorn Diabetes Care System. GoDARTS=Genetics of Diabetes Audit 552 and Research in Taylor in Taylor<br>Research in Taylor<br>Research in Taylor 553 554 Figure 2. (a,b,c) Clinical characteristics and molecular profiles of multi-omics 555 clusters in both DCS and GoDARTS clusters. (d) The hazard ratio for time to<br>556 insulin requirement across clusters. Multi-omics clustering was done without separating the women and men. In each cohort, the statistical difference between 557 cluster 1 and cluster 2 was determined by logistic regression with age, BMI and gender 558 as covariates. Multi-analysed P-values were adjusted by the Benjamini-Hochberg 559 procedure, and a false discovery rate  $(FDR)$ -adjusted P-value  $\leq 0.05$  was considered 560 significant. (a) Distributions of nine clinical measurements at baseline in both DCS and 561 GoDARTS cohorts for each cluster. \*:P-value<=0.05. \*\*:P-value<=0.01. \*\*\*:P-<br>value<=0.001. (**b**) Venn diagrams showing overlaps of significant (significantly different 562 563 value <=0.001. (b) Venn diagrams showing overlaps of significant (significantly different

#### Page **26** of **27**



Figure 3 (a) Comparison of clustering in Slieker and Donnelly et al., 2021 versus 583 Figure 3 (a) Comparison of clustering in Slieker and Donnelly et al., 2021 versus<br>584 clustering in the current study. The first number in each cell represents the number of 584 individuals overlapping, the second number represents the hypergeometric overlap p-<br>value. (**b**) Distributions of nine clinical measurements at baseline in both DCS and 585  $c_n$ DADT $c_n$ echerta for multi-emise slugtere end slinical slugters  $c_{1,1}$  -multi-emise 586 value. (b) Distributions of fine clinical measurements at baseline in both DCS and<br>GoDARTS cohorts for multi-omics clusters and clinical clusters. CL1= multi-omics<br>cluster #1. CL2= multi-omics cluster #2. MD= mild disbates 587 de serves for the continuum cluster consider the clusters considered in the cluster and cluster  $#1$ . CL2= multi-omics cluster  $#2$ . MD= mild diabetes. MDH= mild diabetes v 588 cluster #1. CL2= multi-omics cluster #2. MD= mild diabetes. MDH= mild diabetes with<br>.<br>.

#### Page **27** of **27**

- 
- high HDL. MOD= mild obesity-related diabetes. SIDD= severely insulin deficient<br>diabetes. SIRD= severely insulin resistant diabetes. SBP=systolic blood pressure.
- DBP=diastolic blood pressure. HbA1C=Hemoglobin A1C. DBP=diastolic blood pressure. HbA1C=Hemoglobin A1C.
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 











**Hazard Ratio** 

## Figure 3





